Avian Influenza

New research could lead to potential treatment for avian flu

Published in TB and Outbreaks Week, March 9th, 2004

With the re-emergence of SARS and another outbreak of avian influenza in Asia, many government officials are concerned the outbreaks will increase and a new epidemic will emerge.

In response to this threat, ImmuneRegen BioSciences, a wholly owned subsidiary of IR Biosciences Holdings, Inc., (IRBH) recently completed testing on the Hong Kong influenza virus, which is similar to that of SARS and the avian flu.

Company executives believe this research may indicate efficacy of their proprietary compound, Homspera, in treating the Hong Kong respiratory virus in mice. Additionally, company executives believe these test results are vital to research...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2004-03-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry